Media & Investors
-
Jul 22, 2020TEGSEDI is the first antisense oligonucleotide medicine available to hATTR patients with polyneuropathy in Austria for at-home subcutaneous injection
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that the Main Association of Austrian Social Security Institutions (Dachverband...
-
Jul 21, 2020Webcast scheduled for Tuesday, August 4 at 4:30 p.m. Eastern Time
Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, August 4 at 4:30 p.m. Eastern Time...
-
Jul 20, 2020Dr. Christophe Hotermans joins company, with a decade of clinical practice and 12 years of experience in global biotechnology sector
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Christophe Hotermans, M.D., Ph.D., has joined the company as senior vice...
-
Jul 9, 2020Dr. William Andrews brings two decades of global industry experience, including more than 13 years in rare diseases and seven product launches
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that William Andrews, MD, FACP, has joined the company as chief medical officer...
-
Jun 29, 2020Berns brings more than 20 years of experience in life sciences sector
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Tracy Palmer Berns has joined the company as chief compliance officer. In...
-
Jun 17, 2020
Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases,...
-
Jun 9, 2020Dr. Kia Motesharei joins from Merck KGaA, bringing more than 20 years of experience in the pharmaceutical and biotechnology industry
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Kia Motesharei, Ph.D., has joined the company as Senior Vice President of...
-
Jun 8, 2020TEGSEDI is the first antisense oligonucleotide medicine available to hATTR patients with polyneuropathy in Italy for at-home subcutaneous injection
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that AIFA, or The Italian Medicines Agency, has granted approval for the...
-
Jun 1, 2020TEGSEDI is first antisense oligonucleotide medicine available to patients in Portugal for at-home subcutaneous injection
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the Portuguese Medicine Regulatory Authority (INFARMED) has granted approval for...
-
May 28, 2020Results from the ongoing, open-label extension (OLE) study of the pivotal NEURO-TTR trial published in the European Journal of Neurology show that patients treated with TEGSEDI® (inotersen) experienced sustained improvements in measures of neuropathic progression at 39 months of therapy compared to the natural history of the disease
BOSTON and CARLSBAD, Calif., May 28, 2020 - Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...
-
May 18, 2020Michael D. Price brings more than 25 years of experience in the pharmaceutical industry, including in the rare disease sector
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Michael D. Price has joined the company as executive vice president and...
-
May 14, 2020TEGSEDI is the first antisense medicine available to patients in Spain for at-home subcutaneous injection
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced The Ministry of Health of Spain (MSCBS) has granted approval for the...
-
May 13, 2020
OTTAWA, ON., - May 13, 2020 (CNW) – Akcea Therapeutics Canada, Inc., a subsidiary of Akcea Therapeutics, Inc. (NASDAQ: AKCA), today announced that it has concluded its negotiation with the...
-
May 7, 2020
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Carla Poulson has joined the company as senior vice president and chief...
-
May 5, 2020Achieved First Quarter 2020 Global Net Product Revenues of $15 Million
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing medicines to treat patients with serious and rare...
-
Apr 21, 2020Webcast scheduled for Tuesday, May 5 at 4:30 p.m. Eastern Time
BOSTON, April 21, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on...
-
Mar 24, 2020
BOSTON, March 24, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that its board of directors has appointed
-
Mar 11, 2020
BOSTON, March 11, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Lisa Johnson-Pratt, M.D., has...
-
Feb 28, 2020Company builds awareness of hATTR amyloidosis and FCS via social media campaign, and will host special event with employees, patients and caregivers
BOSTON, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the company’s support for Rare...
-
Feb 26, 2020
BOSTON, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to...
-
Feb 25, 2020Reported Full Year 2019 Global Net Product Revenues of $42 Million and Fourth Quarter 2019 Global Net Product Revenues of $14 Million
BOSTON, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to...
-
Feb 18, 2020Webcast scheduled for Tuesday, February 25 at 4:30 p.m. Eastern Time
BOSTON, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on...
-
Feb 13, 2020
BOSTON, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the appointment of Amber Salzman,...
-
Jan 28, 2020Favorable safety and tolerability were observed
BOSTON and CARLSBAD, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
-
Jan 22, 2020Favorable safety and tolerability were demonstrated in hypertriglyceridemia patients in the study
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced positive topline results from...
-
Jan 10, 2020
BOSTON and CARLSBAD, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
-
Jan 2, 2020Patients treated with AKCEA-APO(a)-LRx received pre-specified endpoints for Lp(a) levels with favorable safety and tolerability profile
BOSTON and CARLSBAD, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
-
Dec 18, 2019Data from Phase 2 clinical trial of AKCEA-APOCIII-LRx anticipated in early 2020
BOSTON and CARLSBAD, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
-
Dec 16, 2019Lynne Parshall appointed chair and Barbara Yanni joins as new member of the Akcea board
BOSTON, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the appointments of Lynne Parshall,...
Dec 4, 2019Alex Howarth joins Akcea from Lycera, bringing more than 25 years of experience in the biopharmaceutical sectorBOSTON, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that Alex Howarth has joined the...
-
Nov 25, 2019
BOSTON and CARLSBAD, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
-
Nov 19, 2019
BOSTON and CARSLBAD, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
-
Nov 13, 2019
BOSTON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to...
-
Nov 5, 2019Reported Third Quarter 2019 Global Net Product Revenues of $12 Million
BOSTON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to...
-
Nov 1, 2019Approval and launch of WAYLIVRA® (volanesorsen) in Europe, the only treatment option for FCS patients, highlights progress in clinical research
BOSTON, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today recognizes Familial...
-
Oct 23, 2019Kyle Jenne promoted from previous role as U.S. commercial lead to support continued strategic expansion of global commercial operations
BOSTON, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that the company has promoted Kyle...
-
Oct 22, 2019Webcast scheduled for Tuesday, November 5th at 4:30 p.m. Eastern Time
BOSTON, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, November 5th
-
Oct 7, 2019Akcea and Ionis to earn $250 million license fee
BOSTON and NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Pfizer Inc. (NYSE:PFE),...
-
Sep 23, 2019Damien McDevitt, Ph.D. appointed interim CEO; Michael Yang and Joseph ‘Skip’ Klein join Board of Directors
BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that its board of directors has appointed
Sep 16, 2019Data show >90% knockdown of TTR following administration in healthy volunteersBOSTON and CARLSBAD, Calif., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:...
Aug 29, 2019Multiple presentations on the long-term efficacy and safety of TEGSEDI® (inotersen) in patients with polyneuropathy caused by hATTR AmyloidosisBOSTON and CARLSBAD, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...
-
Aug 7, 2019Mean triglyceride levels decreased 77% in volanesorsen-treated patients versus an 18% increase in patients in placebo group
BOSTON and CARLSBAD, Calif, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...
-
Aug 6, 2019Achieved Second Quarter 2019TEGSEDI®(inotersen) Global Net Product Revenues of $10 Million
BOSTON, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients...
-
Aug 6, 2019Study meets primary and key secondary endpoints
BOSTON, Mass. and CARLSBAD, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc....
-
Jul 29, 2019Webcast scheduled for Tuesday, August 6th at 4:30 p.m. Eastern Time
BOSTON, July 29, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, August...
-
Jul 16, 2019Akcea and Ambry Genetics grow partnership, providing easily accessible, no-cost, confidential genetic testing and genetic counseling services to people with suspected hereditary ATTR amyloidosis
BOSTON and Aliso Viejo, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ambry Genetics Corporation (“Ambry”),...
-
Jun 26, 2019Multiple clinical presentations focus on the long-term clinical benefits of treatment with TEGSEDI® (inotersen)
BOSTON and CARLSBAD, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...
-
Jun 20, 2019Multiple clinical presentations focus on the long-term clinical benefits of treatment with TEGSEDI® (inotersen)
BOSTON and CARLSBAD, Calif., June 20, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...
-
May 28, 2019
BOSTON, May 28, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with...
-
May 8, 2019Achieved First Quarter 2019TEGSEDI®(inotersen) Global Net Product Revenues of $7 Million
BOSTON, May 08, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients...
-
May 7, 2019WAYLIVRA is the only therapy for Familial Chylomicronemia Syndrome, or FCS, a devastating, ultra-rare disease
BOSTON and CARLSBAD, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS),...
-
May 7, 2019NEURO-TTR phase 3 open-label extension study showed TEGSEDI® (inotersen) treatment continued to slow progression over two-year period in patients with Hereditary ATTR amyloidosis with polyneuropathy
BOSTON and CARLSBAD, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)...
-
May 2, 2019Multiple clinical presentations at AAN focus on the long-term clinical benefits of treatment with TEGSEDI™ (inotersen)
BOSTON, May 02, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that data from the NEURO-TTR...
-
Apr 24, 2019Webcast scheduled for Wednesday, May 8th at 4:30 p.m. Eastern Time
BOSTON, April 24, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Wednesday, May...
-
Mar 15, 2019Presentations focus on the benefits of treatment with TEGSEDI™ (inotersen) and results show continued efficacy with long-term exposure in the NEURO-TTR open-label extension study
BOSTON and CARLSBAD, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)...
-
Mar 1, 2019First and only therapy approved for FCS, a serious and rare disease with no approved treatment options
BOSTON, Mass. and CARLSBAD, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
-
Feb 28, 2019Planned activities to highlight wide-ranging impact of rare diseases on patients and challenges in disease management, including important perspectives from caregivers
BOSTON, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients...
-
Feb 26, 2019TEGSEDI™ (inotersen) commercially available in United States, European Union & Canada
BOSTON, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients...
Feb 25, 2019Phase 3 planning and initiation activities underwayBOSTON and CARLSBAD, Calif., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...
-
Feb 20, 2019
BOSTON, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients...
-
Feb 13, 2019Webcast scheduled for Tuesday, February 26th at 4:30 p.m. Eastern Time
BOSTON, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, February...
-
Nov 29, 2018Presentations focus on the benefits of treatment with TEGSEDI™ (inotersen) and results show continued efficacy with long-term exposure in the NEURO-TTR open-label extension study
BOSTON, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced that it will present the long-term analyses of the...
Nov 12, 2018Approximately 98% of patients receiving highest dose achieved reductions in Lp(a) levels below the established threshold of risk for CVD eventsBOSTON and CARLSBAD, Calif., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...
Nov 8, 2018Results to be presented show a significant reduction of Lp(a) levels, favorable safety and tolerability profileBOSTON and CARLSBAD, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...
-
Nov 6, 2018
BOSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients...
-
Nov 5, 2018TEGSEDITM (inotersen) Approved in United States, European Union & Canada
BOSTON, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients...
-
Nov 2, 2018Community focuses on elevating awareness of the burden of FCS and impact on daily living
BOSTON, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today recognizes the inaugural Familial Chylomicronemia Syndrome...
-
Oct 22, 2018Webcast scheduled for Monday, November 5th at 4:30 p.m. Eastern Time
BOSTON, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Monday, November 5th
-
Oct 8, 2018Dr. Damien McDevitt replaces Dr. Stanley Crooke on Akcea Board of Directors
BOSTON, Oct. 08, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc. today announced that Damien McDevitt, Ph.D. Chief Business Officer of...
-
Oct 5, 2018TEGSEDI is an effective treatment choice that allows self-administration at a time and place that works for the patient
BOSTON and CARLSBAD, Calif., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...
-
Oct 5, 2018Express Scripts’ Accredo® selected as specialty pharmacy for its expertise in providing timely access and support services for patients living with rare diseases
BOSTON, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc.(NASDAQ: IONS), announced today that they are working together with...
-
Oct 4, 2018First and only treatment of its kind for Canadians with Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Polyneuropathy – a rare and inherited disease
OTTAWA and BOSTON and CARLSBAD, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
Sep 24, 2018Study demonstrates significant Lp(a) reduction, favorable safety and tolerability profileCAMBRIDGE, Mass. and CARLSBAD, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
-
Aug 29, 2018
CAMBRIDGE, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc.(NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced that management will present a company...
-
Aug 27, 2018
CAMBRIDGE, Mass. and CARLSBAD, Calif., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA) an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
-
Aug 6, 2018TEGSEDI™ (inotersen) Approved in European Union
CAMBRIDGE, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat...
-
Aug 2, 2018- PTC in-licenses regional rights to TEGSEDI™ and WAYLIVRA™ from Akcea -
PTC Therapeutics, Inc. (NASDAQ: PTCT), and Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced a collaboration under which PTC will...
-
Jul 31, 2018Results from the first-ever study evaluating quality of life in people with FCS and impact of patient connectivity published in Expert Opinion on Orphan Drugs.
CAMBRIDGE, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat...
-
Jul 23, 2018Webcast scheduled for Monday, August 6th at 4:30 p.m. Eastern Time
CAMBRIDGE, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Monday,...
-
Jul 11, 2018
CAMBRIDGE, Mass. and CARLSBAD, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
-
Jul 5, 2018-TEGSEDI treatment demonstrated substantial improvement in measures of neuropathy progression and quality of life-
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, and its affiliate, Akcea Therapeutics (Nasdaq: AKCA), announced today that the final study results from NEURO-TTR,...
-
Jun 13, 2018Results published in Expert Review of Cardiovascular Therapy
CAMBRIDGE, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat...
-
Jun 12, 2018hATTR Compass to provide no-cost, confidential genetic testing and genetic counseling services, potentially enabling faster diagnosis
CAMBRIDGE, Mass., June 12, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ambry Genetics Corporation (“Ambry”), a Konica Minolta
-
Jun 5, 2018
CAMBRIDGE, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced the appointment of Richard (Rich) A....
-
Jun 1, 2018
CAMBRIDGE, Mass. and CARLSBAD, Calif., June 01, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
-
May 29, 2018
CAMBRIDGE, Mass., May 29, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc.(NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced that management will present a company...
-
May 10, 2018FDA Advisory Committee Votes in Favor of WAYLIVRA for Treatment of Familial Chylomicronemia SyndromeAdvisory Committee members vote 12-8 to support approval
CAMBRIDGE, Mass. and CARLSBAD, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
-
May 3, 2018TTR licensing transaction positions Akcea for two rare disease drug launches in 2018
CAMBRIDGE, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat...
-
May 2, 2018Program currently available in the U.S. and select countries in Europe; initiating additional countries throughout 2018
CAMBRIDGE, Mass., May 02, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA) today announced it has expanded its global early access program (EAP) to the United States for people with...
-
Apr 26, 2018Webcast scheduled for Thursday, May 3rd at 4:30 p.m. Eastern Time
CAMBRIDGE, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on...
-
Apr 26, 2018Results to be presented show significant reduction in triglyceride levels associated with reductions of pancreatitis and burden of disease in patients with FCS
CAMBRIDGE, Mass. and LAS VEGAS, April 26, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing...
-
Apr 21, 2018Two oral presentations further demonstrate inotersen’s impact on efficacy and safety and on patient quality of life
CAMBRIDGE, Mass., April 21, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced that data from inotersen’s clinical...
-
Apr 17, 2018
CAMBRIDGE, Mass., April 17, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced that, following today’s close of the...
Apr 17, 2018Akcea shareholders approved the transaction on April 16 at a Special Meeting of StockholdersCAMBRIDGE, Mass. and CARLSBAD, Calif., April 17, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
-
Mar 26, 2018- Advocates Designate First Friday in November as FCS Awareness Day -
CAMBRIDGE, Mass., March 26, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat...
-
Mar 26, 2018Continued benefit with long-term inotersen treatment observed in both quality of life (Norfolk-QOL-DN) and neuropathy (mNIS+7) measures in hATTR amyloidosis patients; Cardiac benefit with inotersen treatment observed in a Phase 2 study in patients with wild-type and hereditary ATTR cardiomyopathy
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, and its affiliate, Akcea Therapeutics, Inc. (Nasdaq: AKCA), today announced Phase 3 data showing that...
-
Mar 21, 2018
LONDON, March 21, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics United Kingdom (UK) Ltd today announced that volanesorsen has been granted a positive scientific opinion through the Early Access to...
-
Mar 15, 2018Ionis licenses to Akcea worldwide rights to inotersen and IONIS-TTR-L Rx
Ionis Pharmaceuticals (NASDAQ: IONS) ("Ionis") and Akcea Therapeutics, Inc. (NASDAQ: AKCA) ("Akcea"), an affiliate of Ionis, today announced an exclusive, worldwide license by Ionis to Akcea for...
-
Mar 12, 2018
CAMBRIDGE, Mass. and CARLSBAD, Calif. , March 12, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), and Ionis...
-
Mar 6, 2018
CAMBRIDGE, Mass., March 06, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat...
